In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Conference call to discuss new data presented for duvakitug (Anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

7 Feb 2025 Yokogawa releases OpreX Quality Management System to accelerate DX in quality assurance processes for the manufacturing of pharmaceuticals ... its industry-leading structure-based ...

Teva Pharmaceutical Indus 30-Day Option Volume & Interest Snapshot Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its ...

Axsome Therapeutics shares were up 14% in premarket trading after reaching a settlement with Teva Pharmaceuticals. Shares were trading around $120.01. The stock is up 8.3% over the last year.

Teva and NICE Systems lost ground as the banks rose. The Tel Aviv Stock Exchange fell today. The Tel Aviv 35 Index fell 0.67%, to 2,491.34 points, the Tel Aviv 125 Index fell 0.37% to 2,564.04 points; ...

Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.

Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 on Wednesday. The company lost over 20% in the preceding six sessions.